SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Microcide Pharmaceuticals (MCDE)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Czechsinthemail who wrote (72)6/1/1997 10:22:00 AM
From: Peter Silsbee   of 186
 
>I tried to follow your link, but couldn't find anything searching for "staph". Any missing steps?

No, I just tried again and it worked fine. In any case, here are the relevant parts (fair use). The page contains abstracts from what I believe are internal presentations at Merck, 1996 and 1997. I'd appreciate comments from anyone to whom this is meaningful!

______________________________
Dr. Mark L. Greenlee, Senior Research Fellow, Department of Medicinal Chemistry, P.O. Box 2000, Rahway, NJ 07065

2-ARYLCARBAPENEMS ACTIVE AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCI

Infections caused by methicillin-resistant staphylococci (MRS) are becoming an increasingly serious problem worldwide. Strains of MRS are almost invariably multiply drug-resistant, including to all currently available beta-lactam antibiotics, and thus the therapeutic options for treating these infections are extremely limited. This presentation will describe the discovery of a new class of 2-arylcarbapenems (1) th potent activity against MRS. The activity of these compounds has been shown to correlate with increased binding to the low affinity penicillin-binding protein PBP-2a present in MRS. The synthesis and biological properties of this new class of antibacterial agents including the structure-activity relationships with respect to the substituents R1 and R2 will be presented.
____________________________________

Dr. Nobuyoshi Yasuda, Research Fellow, Department of Process Research, P.O. Box 2000, Rahway, NJ 07065

PREPARATION OF ANTI-MRSA CARBAPENEMS

Methicillin resistant Staphylococcus aureus (MRSA) causes one of the most fatal infectious diseases. Our Medicinal group has discovered that carbapenems containing aromatic rings at the C-2 position exhibit potent activity against MRSA. Designs of practical syntheses of anti-MRSA carbapenem candidates will be discussed including:

1.Reaction mechanism of Sugasawa reaction-"ortho-acylation of anilines with two Lewis acids"
2.Pschorr cyclization
3.Mild Suzuki cross-coupling with complicated functional moieties
4.Art of the isolation of unstable carbapenems on the large scale

_____

PLS

BTW, I own a bit of MRK but no MCDE (yet).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext